WebJun 1, 2024 · The recently approved anti-CD38 monoclonal antibody daratumumab (DARA) provides a unique therapeutic strategy that more selectively targets plasma cells in patients with plasma cell myeloma. 1-6 While DARA recognizes and removes malignant plasma cells, red blood cells (RBCs) also express CD38. 7 However, many patients on DARA … WebDaratumumab-specific immunofixation reflex assay can be used to distinguish the therapeutic versus disease related M protein. 39 Similarly, CD38 naked antibodies bind to CD38 on red blood cells causing a pan-reactive indirect antiglobulin test on …
CD38-Directed Therapies for Management of Multiple Myeloma
WebPlease notify your blood transfusion laboratory and send a blood sample for extended red blood cell phenotype and RBC antibody screen BEFORE the first dose of … WebCD38 is an integral membrane protein that is highly expressed on myeloma cells that has been shown to be an effective target antigen for monoclonal antibody therapies. There … how do i change my primary email on linkedin
(2024 UPDATE) Daratumumab (Darzalex®) (Multiple Myeloma)
WebNov 12, 2024 · Data suggest that daratumumab could be effective in managing autoimmune hemolytic anemia, antibody-mediated rejection in solid organ transplantation, and various other diseases with autoimmune etiologies. 16 Further studies are needed to observe the incidence of RBC alloimmunization in patients treated with daratumumab … WebPatient will require red cell phenotyping as cross match fails due to binding of daratumumab to red cells. METHOD OF SUBCUTANEOUS DARATUMUMAB ADMINISTRATION: Inject the subcutaneous dose (15 mL) into the subcutaneous tissue of the abdomen approximately 7.5 ... Daratumumab binds to CD38 on red blood cells … WebIf patient red blood cells (RBCs) require phenotyping after the start of daratumumab treatment, dithiothreitol (DTT) treatment of the patient's RBCs should be performed. The … how do i change my printer settings